Vaximm, a Swiss/German biotech company developing oral T-cell immunotherapies, has appointed Matthias Schroff as Chief Executive Officer.
Dr Schroff has more than 15 years of experience in the biotechnology industry.
Previously, he was CEO of Mologen and built the firm from an early preclinical stage to an established immuno-oncology company with programmes in Phase II and III clinical trials.
In addition to his position at Mologen, Dr Schroff also served on the Board of Directors of the biotech arm of the Association of Research-based Pharmaceutical Companies (vfA bio).
During his career, Dr Schroff has served in a variety of functions, including research, manufacturing, scientific collaborations, for example with the MD Anderson Cancer Centre, clinical development, business development and investor relations.
He is the inventor of numerous patents in the field of immuno-oncology, RNAi and gene expression, including a TLR9 agonist that is now in late-stage clinical development for various cancer indications.
Dr Schroff received his PhD in biochemistry from Freie Universität Berlin at the Institute of Molecular Biology and Biochemistry, where he was involved in clinical trials in immunotherapy against cancer as early as 1994.
